Loading...

GANX GAIN THERAPEUTICS INC Delisting Actions 8-K Filing

GN T

GNX

GAIN THERAPEUTICS INC

(GANX)

2025 8-K

Summary

Summary

KOL Event Notification

Director Resignation

Positive Study Results

Equity Offerings

Market Expansion

Increase in authorized shares

Financial Statements

Financial Results

Operational Update

Nasdaq Compliance

Management Changes

Clinical Trial Approval

Nasdaq Compliance

Preclinical Data Release

Financial Results and Busin...

Announcement of Phase 1 stu...

Annual Meeting of Stockholders

Underwriting Agreement

Earnings Reports

CFO Appointment

Financial Results Announcement

Management Changes

Underwriting Agreement and ...

Termination of Agreement

Financial Results

Earnings Reports

Annual Meeting of Stockholders

Earnings Reports

Departure of CFO

Earnings Reports

External Links:

Gain Therapeutics Inc. received a notice from Nasdaq about falling below the $50 million market value requirement but has since regained compliance as of January 14, 2025.

AI Assistant

GAIN THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.